Home » Newsletters » The Carlat Psychiatry Report

The Carlat Psychiatry Report

Antipsychotics Update (March) | 2018

View Archived Issues

CME Post-Test - Antipsychotics Update, TCPR, March 2018

March 1, 2018

The post-test for this issue is available for one year after the publication date to subscribers only. By successfully completing the test you will be awarded a certificate for 1 CME Credit. Read More

Note From the Editor-in-Chief

March 1, 2018

Daniel Carlat, MD

We publish an issue on antipsychotics at least once a year, and it’s always a challenge to decide what to cover. There are dozens of antipsychotics, and most of them are approved for mood disorders as well as psychosis. Read More

Clozapine: A Fresh Look

March 1, 2018

For those reluctant to make clozapine their go-to antipsychotic for certain patients, this article will provide information to help you decide when it’s right to prescribe. Read More

Abilify MyCite: Patient Care Breakthrough or Patent Extender?

March 1, 2018

You’ve probably heard about a new “digital pill” called Abilify MyCite. The product, which was FDA approved in November 2017, is the first drug in the U.S. with a digital ingestion tracking system. Read More

Prescribing and Managing Antipsychotics

March 1, 2018

Thomas Schwartz, MD

For those reluctant to make clozapine their go-to antipsychotic for certain patients, this article will provide information to help you decide when it’s right to prescribe. Read More

QTc Prolongation Risk Management in Hospital Patients

March 1, 2018

Thomas Jordan, MD

Many of the medications we prescribe, most notably antipsychotics and antidepressants, have some risk of QTc prolongation. Since it’s rare to have complications of a prolonged QTc interval—such as torsades de pointes (TdP) and sudden cardiac death—clinics and hospitals typically don’t screen for it using electrocardiograms (ECG). Read More